Urolog. pro Praxi, 2004; 2: 57-58

Urogenitální atrofie: lokální HRT - nejlepší volba?

MUDr. Jiří Labounek1, MUDr. Dušan Fügner2
1 Porodnicko-gynekologické odd. Nemocnice Šumperk, s. r. o
2 Urologické oddělení Nemocnice Šumperk

Keywords: urogenital atrophy, estrogens, local treatment, sexual dysfunctions.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Labounek J, Fügner D. Urogenitální atrofie: lokální HRT - nejlepší volba? Urol. praxi. 2004;5(2):57-58.

Nedostatek estrogenů působící urogenitální atrofii podstatně zhoršuje kvalitu života žen po menopauze. Systémová HRT přitom zdaleka ne ve všech případech dokáže odstranit symptomy atrofie; 10-25 % uživatelek při celkové estrogenní substituci nenachází úlevu od urogenitálních symptomů. Místní podávání estrogenů se zdá být podle mnoha sdělení výhodnější. Vaginální podávání byť velmi malého množství estrogenů přesvědčivě zlepšuje trofiku tkaniv urogenitálního traktu a tím omezuje výpadovou urogenitální symptomatologii, bez měřitelného zvýšení hladiny estrogenů v plazmě a bez rizika vzniku karcinomu endometria či prsu.

UROGENITAL ATROPHY: LOCAL TREATMENT - THE BEST SOLUTION?

The lack of estrogens causing urogenital atrophy is significantly worsening the quality of life in the group of women after menopause. Systemic administration of HRT can not absolutely solve the symptoms because 10-25 % women with HRT still remain symptomatic. Local treatment of estrogens seems to be more convincible. Vaginal administration of small dosis of estrogens can significantly improve the trophical status of urogenital system and diminish patients- troubles. This is without increased level of estrogens in peripheral blood and without danger from endometrial or breast cancer.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Botsis D, Kassanos D, Kalogirou D, et al. Vaginal ultrasound of the endometrium in postmenopausal women with symptoms of urogenital atrophy on low-dose estrogen or tibolone treatment: a comparison. Maturitas 1997; 26(1): 57-62. Go to original source... Go to PubMed...
    2. Cardozo L, Bachmann G, McClish D et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women. Obstet Gynecol 1998; 92(4 Pt 2): 722-7. Go to original source... Go to PubMed...
    3. Cardozo L, Robinson D. Special considerations in premenopausal and postmenopausal women with symptoms of overactive bladder. Urology 2002; 60 (5 Suppl 1): 64-71. Go to original source... Go to PubMed...
    4. Davila GW, Singh A, Karapanagiotou I, et al. Are women with urogenital atrophy symptomatic? Am J. Obstet Gynecol 2003; 188 (2): 382-388. Go to original source... Go to PubMed...
    5. Hodgins MB, Spike RC, Mackie RM, MacLean AB. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol 1998; 105: 216-22. Go to original source... Go to PubMed...
    6. Iosif S, et al. Estrogen receptors in the human female lower urinary tract. Am.J.Obstet. Gynec 1981; 141: 817-820. Go to original source... Go to PubMed...
    7. Keil K. Urogenital Atrophy: Diagnosis, Sequelae, and Management, Current Women's Health Reports 2002; 2: 305-311.
    8. Krofta L., Feyreisel J. Hormonální léčba v urogynekologii. Moderní gyn a por 9/2000; 3: 512-519.
    9. Leiblum S, Bachmann G. Kemmann E, et al. Vaginal atrophy in the postmenopausal woman. The importance of sexual activity and hormones. JAMA 1983; Apr 22-29; 249 (16): 2195-2198. Go to original source... Go to PubMed...
    10. Lindsay R, Scotti RJ, Mikhail M, et al. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol 2003; 189 (1): 81-88. Go to original source... Go to PubMed...
    11. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women (Cochrane Methodology Review). In: The Cochrane Library, Issue, 2003; 4. Go to original source... Go to PubMed...
    12. Notelovitz M. Urogenital atrophy and low-dose vaginal estrogen therapy (editorial). Menopause 2000; 7: 140-142. Go to original source... Go to PubMed...
    13. Palmer A, Likis FE. Lactational Atrophic Vaginitis, J Midwifery Womens Health 2003; 48 (4): 282-284, Pharmacotherapy 2001; 21 (4): 464-480. Go to original source... Go to PubMed...
    14. Pschera H, Hjerpe A, Carlstrom K. Influence of the maturity of the vaginal epithelium upon the absorption of vaginally administered estradiol-17 beta and progesterone in postmenopausal women. Gynecol Obstet Invest 1989; 27 (4): 204-207. Go to original source... Go to PubMed...
    15. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction, Urology, 2003; 62: Issue 4 (Sup. 1): 45-41. Go to original source... Go to PubMed...
    16. Robinson D, Cardozo LD. The role of estrogens in female lower urinary tract dysfunction. Urology 2003; 62 (4 Suppl 1): 45-51. Go to original source... Go to PubMed...
    17. Samsioe G. Urogenital aging - a hidden problemAm. J. Obstet Gynecol 1998; 178 (5): S245-9. Go to original source... Go to PubMed...
    18. Simunic V, Banovic I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003; 82 (2):187-197. Go to original source... Go to PubMed...
    19. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane From The Cochrane Library, 2003; Issue 4. Go to original source...
    20. Weinberger MW, Goodman BM, Long-term efficacy of nonsurgical urinary incontinence treatment in elderly women. J Gerontol A Biol Sci Med Sci 1999; 54 (3): M117-21. Go to original source... Go to PubMed...
    21. Willhite A., O'Connell MB. Urogenital Atrophy: Prevention and Treatment.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.